Evidence map›Paper›PMID 40090715›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma.

Masahiro Akimoto, Takuya Miyazaki, Hiroyuki Takahashi, Takaaki Takeda, Yuto Hibino, Mayumi Tokunaga, Takuma Ohashi, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Masahiro AkimotoDepartment of Hematology, Yokohama City University Medical Center, Japan.
Takuya MiyazakiDepartment of Hematology, Yokohama City University Medical Center, Japan.
Hiroyuki TakahashiDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Japan.
Takaaki TakedaDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Japan.
Yuto HibinoDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Japan.
Mayumi TokunagaDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Japan.
Takuma OhashiDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan.
Ayako MatsumuraDepartment of Hematology, Yokohama City University Medical Center, Japan.
Haruka TeshigawaraDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan.
Taisei SuzukiDepartment of Hematology, Fujisawa City Hospital, Japan.
Hiroshi TeranakaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan.
Yuki NakajimaDepartment of Hematology, Yokohama City University Medical Center, Japan.
Kenji MatsumotoDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan.
Chizuko HashimotoDepartment of Hematology/Oncology, Yamato Municipal Hospital, Japan.
Katsumichi FujimakiDepartment of Hematology, Fujisawa City Hospital, Japan.
Hiroyuki FujitaDepartment of Hematology, Saiseikai Yokohama Nanbu Hospital, Japan.
Rika SakaiDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Japan.
Shin FujisawaDepartment of Hematology, Yokohama City University Medical Center, Japan.
Hideaki NakajimaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective High-dose methotrexate (HD-MTX) is widely used as central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL) who are at a high risk of CNS relapse. Ensuring safe prophylactic administration with minimal adverse events is a key concern; however, few studies have detailed the safety profile of HD-MTX prophylaxis in patients with high-risk DLBCL. We analyzed the adverse events associated with HD-MTX in this population, focusing on delayed MTX elimination. Methods This multicenter retrospective study included 98 patients with DLBCL at high risk of CNS relapse who received HD-MTX as part of frontline therapy between 2014 and 2020. CNS prophylaxis involved 2 cycles of HD-MTX (3.0 g/m

Indexed as

Antimetabolites, AntineoplasticCentral Nervous System NeoplasmsLymphoma, Large B-Cell, DiffuseMethotrexateAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesAntimetabolites, AntineoplasticMethotrexatecentral nervous system prophylaxiscentral nervous system relapsedelayed MTX eliminationdiffuse large B-cell lymphomahigh-dose methotrexate

Identifiers

PMID40090715
PMCPMC12508606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.